KMKevin D. Mlynek

Kevin D. Mlynek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kevin D. Mlynek has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Joel A. Bozue

    Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, USA

    6 shared publications
  • Ju Qiu

    Biostatistics Branch, US Army Medical Research Institute of Infectious Diseases (USAMRIID)

    6 shared publications
  • Ronald G. Toothman

    Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, United States

    5 shared publications
  • Christopher P. Klimko

    Bacteriology Division, US Army Medical Research Institute of Infectious Diseases (USAMRIID)

    3 shared publications
  • Elsie E. Martinez

    Bacteriology Division, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD, United States

    3 shared publications
  • Sherry Mou

    Bacteriology Division, US Army Medical Research Institute of Infectious Diseases (USAMRIID)

    3 shared publications

Latest Publications

  • Open Access

    Characterization of an isogenic bimA mutant in the ATS2021 strain of Burkholderia pseudomallei

    by Christopher K. Cote, Sherry Mou, Michael L. Davies, Kevin D. Mlynek, Christopher P. Klimko, Sergei S. Biryukov, Nathaniel O. Rill, Jennifer L. Dankmeyer, Taloria K. Wheeler, Carlos I. Rodriguez, et al.

    Encephalomyelitis is uncommon but is associated with Burkholderia pseudomallei strains whose bimA gene, encoding an actin-based motility protein, resembles bimA from Burkholderia mallei (designated bimA Bm ). We previously characterized the virulence of B. pseudomallei wild-type ATS2021 ( bimA Bm ). In a mouse model of ATS2021 aerosol exposure, lesions and inflammatory cytokines in the brain were seen early post-exposure and reached the central nervous system (CNS) through the olfactory nerve. In the current study, the bimA allele in the wild-type ATS2021 was replaced with the bimA Bp , and virulence was assessed by estimations of LD 50 , histopathological analyses, and bacterial dissemination. ATS2021 bimA Bp reached the CNS but was significantly attenuated, with higher LD 50 estimates, altered bacterial dissemination, and reduced neuroinflammation. The immune response in lungs, spleens, and brains from mice exposed to aerosols indicated either strain induced shared and divergent immune patterns. Finally, the evaluation of the host response in brains via NanoString transcriptomic platform analyses suggested that the wild-type ATS2021 induced substantial changes in astrocyte and microglial activation, oligodendrocyte function, and overall inflammatory signaling, compared to the mutant bimA Bp bacteria. These results support a direct role of the bimA Bm gene product for bacterial dissemination after inhalation.


  • Open Access

    Animal modelling with the Francisella tularensis subspecies holarctica strain OR96-0246

    by Kevin D. Mlynek, Sara I. Ruiz, Curtis R. Cline, Alexandra N. Jay, Ju Qiu, Ronald G. Toothman, Elsie E. Martinez, Wannaporn Ittiprasert, Nancy A. Twenhafel, Joel A. Bozue

    Tularemia is a zoonotic disease caused by Francisella tularensis . Most human cases are caused by F. tularensis ssp. tularensis (type A) or F. tularensis ssp. holarctica (type B), with the former considered more virulent. For this reason, type A isolates are often the benchmark for the testing of new vaccines or antibiotics. However, both subspecies cause considerable disease and can differ in their responsiveness to medical countermeasures. Accordingly, there is a need to identify and characterize representative type B isolates that are available to qualified research institutions to ensure the development of future vaccines or antibiotics is efficacious against both subspecies. The type B isolate OR96-0246 was identified as a strain that can address this need and was subsequently characterized. For in vitro characterization, the OR96-0246 strain was examined for growth in media and for its ability to form biofilm. As the LPS is an essential virulence factor, the O-antigen was characterized through western analysis. For future medical countermeasure testing for biodefence concerns, pneumonic challenges with animal modelling would be required. Therefore, using the OR96-0246 strain, we implemented animal models that encompassed BALB/c mice, Fischer 344 rats and cynomolgus macaques. Mice were challenged via intranasal instillation with varying doses of OR96-0246, and the LD 50 was determined to be 1 c.f.u. We progressed to Fischer 344 rats, which are a better-suited rodent model to gauge vaccine efficacy. When challenging the rats by whole body aerosolization with various doses of OR96-0246, the LD 50 was determined to be 138 c.f.u. Finally, a staircase challenge design was applied to three cynomolgus macaques, each receiving a different aerosolized dose of OR96-0246 to determine an estimated LD 50 for non-human primates (NHPs). Two out of the three NHPs succumbed to the challenge. The animal that received the lowest dose (2.1×10 4 c.f.u.) survived but did demonstrate clinical signs of infection. Samples from the challenged rats and NHPs were collected for histopathology characterization. Generally, the pathological changes observed in both models were similar, consisting primarily of multifocal bronchopneumonia in the lung and necrotic lesions in the spleen. This animal model development with type B strains of F. tularensis will be essential to properly evaluate new antimicrobials and vaccines to protect against tularemia.


  • Open Access

    Virulence and genome analysis of three historical Francisella tularensis ssp. holarctica isolates for development of a Type B test panel

    by Kevin D. Mlynek, Joshua B. Richardson, Elsie E. Martinez, Ronald G. Toothman, Ju Qiu, Curtis R. Cline, Joel A. Bozue

    Francisella tularensis ssp . tularensis (Type A) and ssp. holarctica (Type B) are the etiological agent of tularemia. Most studies on F. tularensis pathogenesis and vaccine development have focused on the Type A Schu S4 strain. However, Type B isolates remain less understood, emphasizing the need for further research. To address this concern and provide well characterized Type B isolates to test future vaccine efficacy, we selected three Type B isolates available in the USAMRIID repository (VT68, strain 425, and strain 503). These strains were chosen based on the original isolation source, the availability of historical in vivo data, and genomic sequence data. Strains were characterized for extracellular and intracellular growth, lipopolysaccharide profile via western blot analysis, and LD 50 values were determined by both murine intranasal challenge and aerosolization of Fischer 344 rats. Strain 425 displayed several attenuation indicators and was completely attenuated in a rat aerosol challenge model. In contrast, VT68 and 503 remained highly virulent in rodent models but displayed some differences in lesion severity. Although F. tularensis genomes are known to be highly conserved, genomic analysis revealed multiple inversions and 68 unique genetic differences among these three Type B isolates. From this study, we were able to provide well-characterized Type B F. tularensis strains to test future vaccines and therapeutics.

  • Open Access

    Implementation of a post-exposure tularemia treatment model for pneumonic challenged Fischer rats

    by Kevin D. Mlynek, J. Matthew Meinig, Melissa Teague, Robert Edwards, Ronald G. Toothman, Elsie Martinez, Christopher P. Klimko, Sherry Mou, Christian Xander, Eugene Blue, et al.


  • Open Access

    Treatment of bacterial biothreat agents with a novel purified bioactive lactoferrin affects both growth and biofilm formation

    by Christian Xander, Elsie E. Martinez, Ronald G. Toothman, Christina L. Gardner, Ju Qiu, Jonathan Snedeker, Matthew H. Bender, Christopher Hlubb, Crystal W. Burke, Joel A. Bozue, et al.

    Lactoferrin is known to exhibit broad spectrum activity against a multitude of bacteria, fungi, and viruses due to its multi-functional mode of action. Recently, Lactea Therapeutics and its affiliates have developed a novel, patent-pending technology to purify naturally derived bovine lactoferrin (Lactea Lf) for use as a medical countermeasure that was not previously available. To assess the efficacy of Lactea Lf against biothreat pathogens, we performed biofilm inhibition assays and generated dose-response curves against Burkholderia pseudomallei, Burkholderia mallei, and Francisella tularensis for proof-of-principle studies. Here, we show that Lactea Lf can significantly inhibit biofilm and decrease the overall growth in a dose dependent manner for all Burkholderia species tested. Of note, Lactea Lf was found to completely inhibit biofilm formation by virulent B. pseudomallei without observing complete growth inhibition. The growth of F. tularensis was also significantly inhibited when cultured in the presence of Lactea Lf and appeared more sensitive to treatment when compared to B. pseudomallei. Based on these results, a pneumonic infection model using the F. tularensis LVS strain was performed prophylactically administering Lactea Lf and continuing treatment post challenge. No protection was observed in this model which prompted biodistribution studies using fluorescent tagged Lactea Lf. These experiments revealed that therapeutic material was mainly confined to the NALT region following intranasal delivery and then quickly dispersed or inactivated suggesting that future formulation and delivery method could be addressed to increase in vivo treatment efficacy. Taken together, these data support that Lactea Lf is a potentially new candidate for further studies as a broad-spectrum antimicrobial medical countermeasure with efficacy against several high priority biodefense-related bacterial pathogens.


  • Open Access

    Mutation of wbtJ, a N-formyltransferase involved in O-antigen synthesis, results in biofilm formation, phase variation and attenuation in Francisella tularensis

    by Kevin D. Mlynek, Ronald G. Toothman, Elsie E. Martinez, Ju Qiu, Joshua B. Richardson, Joel A. Bozue

    Two clinically important subspecies, Francisella tularensis subsp. tularensis (type A) and F. tularensis subsp. holarctica (type B) are responsible for most tularaemia cases, but these isolates typically form a weak biofilm under in vitro conditions. Phase variation of the F. tularensis lipopolysaccharide (LPS) has been reported in these subspecies, but the role of variation is unclear as LPS is crucial for virulence. We previously demonstrated that a subpopulation of LPS variants can constitutively form a robust biofilm in vitro, but it is unclear whether virulence was affected. In this study, we show that biofilm-forming variants of both fully virulent F. tularensis subspecies were highly attenuated in the murine tularaemia model by multiple challenge routes. Genomic sequencing was performed on these strains, which revealed that all biofilm-forming variants contained a lesion within the wbtJ gene, a formyltransferase involved in O-antigen synthesis. A ΔwbtJ deletion mutant recapitulated the biofilm, O-antigen and virulence phenotypes observed in natural variants and could be rescued through complementation with a functional wbtJ gene. Since the spontaneously derived biofilm-forming isolates in this study were a subpopulation of natural variants, reversion events to the wbtJ gene were detected that eliminated the phenotypes associated with biofilm variants and restored virulence. These results demonstrate a role for WbtJ in biofilm formation, LPS variation and virulence of F. tularensis.


  • Open Access

    The rLVS Δ capB / iglABC vaccine provides potent protection in Fischer rats against inhalational tularemia caused by various virulent Francisella tularensis strains

    by Kevin D. Mlynek, Curtis R. Cline, Sergei S. Biryukov, Ronald G. Toothman, Beth A. Bachert, Christopher P. Klimko, Jennifer L. Shoe, Melissa Hunter, Zander M. Hedrick, Jennifer L. Dankmeyer, et al.

    Francisella tularensis is one of the several biothreat agents for which a licensed vaccine is needed. To ensure vaccine protection is achieved across a range of virulent F. tularensis strains, we assembled and characterized a panel of F. tularensis isolates to be utilized as challenge strains. A promising tularemia vaccine candidate is rLVS ΔcapB/iglABC (rLVS), in which the vector is the LVS strain with a deletion in the capB gene and which additionally expresses a fusion protein comprising immunodominant epitopes of proteins IglA, IglB, and IglC. Fischer rats were immunized subcutaneously 1-3 times at 3-week intervals with rLVS at various doses. The rats were exposed to a high dose of aerosolized Type A strain Schu S4 (FRAN244), a Type B strain (FRAN255), or a tick derived Type A strain (FRAN254) and monitored for survival. All rLVS vaccination regimens including a single dose of 107 CFU rLVS provided 100% protection against both Type A strains. Against the Type B strain, two doses of 107 CFU rLVS provided 100% protection, and a single dose of 107 CFU provided 87.5% protection. In contrast, all unvaccinated rats succumbed to aerosol challenge with all of the F. tularensis strains. A robust Th1-biased antibody response was induced in all vaccinated rats against all F. tularensis strains. These results demonstrate that rLVS ΔcapB/iglABC provides potent protection against inhalational challenge with either Type A or Type B F. tularensis strains and should be considered for further analysis as a future tularemia vaccine.


  • Open Access

    Why vary what’s working? Phase variation and biofilm formation in Francisella tularensis

    by Kevin D. Mlynek, Joel A. Bozue

    The notoriety of high-consequence human pathogens has increased in recent years and, rightfully, research efforts have focused on understanding host-pathogen interactions.Francisella tularensishas been detected in an impressively broad range of vertebrate hosts as well as numerous arthropod vectors and single-celled organisms. Two clinically important subspecies,F. tularensissubsp.tularensis(Type A) andF. tularensissubsp.holarctica(Type B), are responsible for the majority of tularemia cases in humans. The success of this bacterium in mammalian hosts can be at least partly attributed to a unique LPS molecule that allows the bacterium to avoid detection by the host immune system. Curiously, phase variation of the O-antigen incorporated into LPS has been documented in these subspecies ofF. tularensis,and these variants often display some level of attenuation in infection models. While the role of phase variation inF. tularensisbiology is unclear, it has been suggested that this phenomenon can aid in environmental survival and persistence. Biofilms have been established as the predominant lifestyle of many bacteria in the environment, though, it was previously thought that Type A and B isolates ofF. tularensistypically form poor biofilms. Recent studies question this ideology as it was shown that alteration of the O-antigen allows robust biofilm formation in both Type A and B isolates. This review aims to explore the link between phase variation of the O-antigen, biofilm formation, and environmental persistence with an emphasis on clinically relevant subspecies and how understanding these poorly studied mechanisms could lead to new medical countermeasures to combat tularemia.


  • Open Access

    Extracellular polymeric substance (EPS)-degrading enzymes reduce staphylococcal surface attachment and biocide resistance on pig skin in vivo

    by Jeffrey B Kaplan, Kevin D Mlynek, Hashani Hettiarachchi, Yonas A Alamneh, Lionel Biggemann, Daniel V Zurawski, Chad C Black, Charles E Bane, Robert K Kim, Mark S Granick

    Staphylococcal extracellular polymeric substances (EPS) such as extracellular DNA (eDNA) and poly-N-acetylglucosamine surface polysaccharide (PNAG) mediate numerous virulence traits including host colonization and antimicrobial resistance. Previous studies showed that EPS-degrading enzymes increase staphylococcal biocide susceptibility in vitro and in vivo, and decrease virulence in animal models. In the present study we tested the effect of EPS-degrading enzymes on staphylococcal skin colonization and povidone iodine susceptibility using a novel in vivo pig model that enabled us to colonize and treat 96 isolated areas of skin on a single animal in vivo. To quantitate skin colonization, punch biopsies of colonized areas were homogenized, diluted, and plated on agar for colony forming unit enumeration. Skin was colonized with either Staphylococcus epidermidis or Staphylococcus aureus. Two EPS-degrading enzymes, DNase I and the PNAG-degrading enzyme dispersin B, were employed. Enzymes were tested for their ability to inhibit skin colonization and detach preattached bacteria. The effect of enzymes on the susceptibility of preattached S. aureus to killing by povidone iodine was also measured. We found that dispersin B significantly inhibited skin colonization by S. epidermidis and detached preattached S. epidermidis cells from skin. A cocktail of dispersin B and DNase I detached preattached S. aureus cells from skin and increased their susceptibility to killing by povidone iodine. These findings suggest that staphylococcal EPS components such as eDNA and PNAG contribute to skin colonization and biocide resistance in vivo. EPS-degrading enzymes may be a useful adjunct to conventional skin antisepsis procedures in order to further reduce skin bioburden.